Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Pharmacology stubs
Arginine/lysine
Другие языки:

    Arginine/lysine

    Подписчиков: 0, рейтинг: 0

    Arginine/lysine
    Combination of
    Arginine Amino acid
    Lysine Amino acid
    Clinical data
    Trade names LysaKare
    License data
    Routes of
    administration    		 Intravenous infusion
    ATC code
    Legal status
    Legal status
    • EU: Rx-only
    Identifiers
    CAS Number
    KEGG

    Arginine/lysine, sold under the brand name LysaKare, is a fixed-dose combination medication used to protect the kidneys from radiation damage during cancer treatment with a radioactive medicine called lutetium (177Lu) oxodotreotide. It contains L-arginine hydrochloride and L-lysine hydrochloride.

    The most common side effects include nausea and vomiting. Arginine/lysine is also associated with hyperkalaemia (high blood potassium levels), but the frequency of this side effect is not known. Side effects with arginine/lysine are usually mild or moderate.

    Radiation from lutetium (177Lu) oxodotreotide can cause damage when the medicine passes through tubules in the kidney. Arginine and lysine interfere with the passage of lutetium (177Lu) oxodotreotide through these kidney tubules. As a result, the radioactive medicine leaves the body in the urine and the kidneys are exposed to less radiation.

    Arginine/lysine was approved for medical use in the European Union in July 2019.

    Medical uses

    Arginine/lysine is indicated for reduction of renal radiation exposure during peptide receptor radionuclide therapy (PRRT) with lutetium (177Lu) oxodotreotide in adults.

    External links

    • "Arginine". Drug Information Portal. U.S. National Library of Medicine.
    • "Lysine". Drug Information Portal. U.S. National Library of Medicine.



    Новое сообщение